Table 5 The significant module genes-targeted small molecule drugs predicted using the CMap database
Small molecular drugs | Cell line | Mechanism of action | Target gene | − log10 FDR | Normalized WTCS values |
|---|---|---|---|---|---|
Halcinonide | HA1E | Glucocorticoid receptor agonist | NR3C1 | 1.7918 | 1.8832 |
GSK-1904529A | A549 | IGF-1 inhibitor | IGF1R|INSR | 1.6662 | 1.8579 |
SEW-2871 | VCAP | Lysophospholipid receptor agonist | S1PR1 | 1.585 | 1.8371 |
SSR-69071 | MCF7 | Leukocyte elastase inhibitor | ELANE | 1.4601 | 1.7966 |
Fenobam | A375 | Glutamate receptor antagonist | GRM5 | 1.439 | 1.7886 |
BRD-K33583600 | HEPG2 | Guanylate cyclase activator | AKR1B1|HRH2|SIRT1|GABBR1 | 1.3241 | 1.7371 |
CP-55940 | HCC515 | Cannabinoid receptor agonist | CNR1|CNR2|GPR55 | 1.3225 | 1.7362 |
Dipyridamole | MDAMB231 | Phosphodiesterase inhibitor | PDE5A | 1.3177 | 1.7337 |
Estrone | HCC515 | Estrogen receptor agonist | ESR1|ESR2 | 1.2876 | 1.7176 |
Ixazomib | HEPG2 | Proteasome inhibitor | PSMB1 | 1.2793 | 1.7129 |
I-BET-762 | OCILY3 | Bromodomain inhibitor | BRD2|BRD3|BRD4|APOA1 | 0.9565 | − 1.6703 |
SB-590885 | HCC515 | RAF inhibitor | BRAF | 0.9565 | − 1.686 |
Methylnorlichexanthone | HA1E | Aurora kinase inhibitor|PIM inhibitor|VEGFR inhibitor | AURKB|PIM1 | 0.9565 | − 1.6863 |
CHIR-99021 | HA1E | GSK inhibitor | CDK1|GSK3A|GSK3B|MAPK1 | 0.9565 | − 1.6981 |
Enalapril | HA1E | ACE inhibitor | ACE | 0.9565 | − 1.7012 |
XMD-1150 | OCILY3 | LRRK inhibitor | LRRK2 | 0.9565 | − 1.7161 |
Nimesulide | HCC515 | Cyclooxygenase inhibitor | PTGS2|LTF|PLA2G2E|PTGS1 | 0.9565 | − 1.7362 |
Olopatadine | PC3 | Histamine receptor antagonist | HRH1 | 0.9565 | − 1.7392 |
Oxalomalic-acid | A549 | Isocitrate dehydrogenase inhibitor | ACO1|IDH1 | 0.9565 | − 1.7631 |
PTB1 | HEPG2 | AMPK activator | PTPN1 | 0.9565 | − 1.8713 |
Mepacrine | THP1 | NFKB inhibitor|Cytokine production inhibitor|p53 activator | PLA2G2A | 0.0953 | 0.9348 |
Mepacrine | NCIH508 | NFKB inhibitor|Cytokine production inhibitor|p53 activator | PLA2G2A | 0.0853 | 0.9055 |
Mepacrine | HUVEC | NFKB inhibitor|Cytokine production inhibitor|p53 activator | PLA2G2A | 0.0114 | 0.7241 |
Mepacrine | H1299 | NFKB inhibitor|Cytokine production inhibitor|p53 activator | PLA2G2A | 0.0058 | 0.6972 |
Mepacrine | MCF10A | NFKB inhibitor|Cytokine production inhibitor|p53 activator | PLA2G2A | 0 | 0.6437 |
Mepacrine | MDAMB231 | NFKB inhibitor|Cytokine production inhibitor|p53 activator | PLA2G2A | 0.0794 | − 0.9696 |
Mepacrine | NCIH596 | NFKB inhibitor|Cytokine production inhibitor|p53 activator | PLA2G2A | 0.0983 | − 1.0372 |
Mepacrine | A375 | NFKB inhibitor|Cytokine production inhibitor|p53 activator | PLA2G2A | 0.2388 | − 1.259 |
Mepacrine | NCIH2073 | NFKB inhibitor|Cytokine production inhibitor|p53 activator | PLA2G2A | 0.2899 | − 1.3061 |
Mepacrine | HCC515 | NFKB inhibitor|Cytokine production inhibitor|p53 activator | PLA2G2A | 0.4515 | − 1.4688 |